Shenzhen Airlines Launches Direct Flight From Shenzhen to Barcelona Successfully
28.8.2023 21:04:00 EEST | Business Wire | Press release
The flight ZH9065 with 203 passengers on board, which took off from Shenzhen of China, landed in Barcelona of Spain in the morning on August 28, marked the new direct flight has been launched successfully by Shenzhen Airlines.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230828849009/en/
Zhou Zhiwei(L6), board member and executive vice president of Shenzhen Airlines, and Hu Aimin(L5), the deputy consul-general of China in Barcelona, welcome the cabin crew and passengers of the debut flight of Shenzhen-Barcelona route in Barcelona on August 28. (Photo: Business Wire)
Together with the Barcelona municipality, the general consulate of China in Barcelona, the Air Routes Development Committee in Barcelona (CDRA), Network of airports in Spain (AENA), the Shenzhen airlines and its partner Air China, organized a warm ceremony to welcome the passengers, while the major of Barcelona, the deputy consul-general of China in Barcelona, and dozens of representatives of those organizers attended the event.
The round flight connecting Shenzhen and Barcelona is operated by Shenzhen Airlines twice a week, on every Monday and Friday. Flight ZH9066 from Barcelona to Shenzhen departs at 11:30 local time and arrives at 07:00 Beijing time, the return flight ZH9065 departs at 11:30 and arrives at 08:05.
The advanced Airbus A330 wide-body passenger aircraft has been invested in this new route, which brings every people a comfortable journey.
In addition, passengers taking this flight are provided with cross-city transfers, free transit hotels, express visa process, and other exclusive services.
Shenzhen Airlines was established in 1992 in Shenzhen, one of the core cities of the Guangdong-Hong Kong-Macao Greater Bay Area in China. With 226 passenger aircraft of various types, the fleet of Shenzhen Airlines ranks the fifth in China. Supporting by 15 branches or bases across the whole country, Shenzhen Airlines operates now more than 200 routes, covering the major destinations in China and abroad.
Shenzhen is one of the five major airports in China, also an important transportation hub in the Asia-Pacific region, plays an important role for connecting China and the other countries.
2023 marks the 50th anniversary of the establishment of diplomatic relations between Spain and China, and the second anniversary of Barcelona and Shenzhen becoming sister cities. The new route sets up a convenient air bridge between the two cities, which will further promote the cooperation between the two places and even between the two nations in the fields of sci-tech, culture, tourism, and trade.
The new route is Shenzhen Airlines' second direct flight from Europe following the first one between London and Shenzhen. Shenzhen Airlines will continue to enrich the route network in near future.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230828849009/en/
Contact information
Z. Pan info@xinhuaeurope.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 12:52:00 EEST | Press release
The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not merely a wage dispute. It stems from deep structural concerns regarding the company’s ESG management, lack of operational autonomy, and passive labor relations. Primarily, the union highlighted unresolved corporate governance issues, including allegations concerning unfair labor practices and the unauthorized use of employee personal data, which were prominently reported by South Korea's major broadcaster, MBC, in November 2025. The union believes this crisis stems from management's failure to address r
The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 12:00:00 EEST | Press release
The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that elevates high-performance riders and horses to their rightful place on the world stage. Built on merit, integrity, and excellence, the PJL brings together the world’s best athletes to compete for the biggest prize pot in the discipline’s history, helping to create a more resilient, long-term financial model for the sport. Represented by sixteen teams, the PJL will introduce an industry-first rider selection process from a pool of 250 of the world’s leading riders. World-class, immersive events will unfold across fourteen ic
Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 12:00:00 EEST | Press release
Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkbj) for the treatment of spastic cerebral palsy (CP). On top of safety and tolerability, the study will evaluate improvements in daily functioning, quality of life, motor abilities, and neurodevelopmental measures of the Cenegermin-bkbj intranasal formulation. CP is the most common motor disability in childhood, caused by injury or changes during early brain development. The most prevalent form, spastic CP, leads to muscle stiffness and difficulty with movement.2 “Cerebral palsy is a devastating disease, and for patients and families there are still no proven treatments beyond supportive care,” said Marcello Allegretti, Chief Scientific Officer at Dompé. “With our emerging intranasal NGF p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom